Ensitrelvir After COVID Exposure

What did the new ensitrelvir analyses find?

The analyses, presented by Shionogi at IDWeek 2026, drew on SCORPIO-PEP, a randomized, placebo-controlled phase 3 trial of post-exposure prophylaxis among household contacts. Among participants who later tested positive, mean peak viral RNA levels were lower in the ensitrelvir group than in the placebo group. The company also reported a lower proportion of severe symptoms in a subgroup with symptomatic breakthrough infections.

These results need careful interpretation. The analyses were exploratory and focused on subsets of trial participants; the reported comparisons do not show that ensitrelvir is an established treatment for people who already have symptomatic COVID-19. Viral RNA is also a laboratory measure, and a difference in that measure does not by itself establish a meaningful change in illness, contagiousness, or complications.

What does the evidence mean for people exposed to COVID-19?

The primary SCORPIO-PEP trial studied people who had been exposed to an infected household member and began a five-day course soon after that person developed symptoms. The trial report in the New England Journal of Medicine found that prompt ensitrelvir post-exposure prophylaxis reduced the risk of symptomatic COVID-19 compared with placebo. That primary result is distinct from the later exploratory analyses of participants who became infected or had infection detected at enrollment.

Ensitrelvir is an oral antiviral that inhibits the SARS-CoV-2 main protease, an enzyme the virus uses to replicate. In the United States, the drug is authorized for post-exposure prophylaxis in adults and adolescents aged 12 years and older following contact with someone who has COVID-19; it is not approved there to treat COVID-19. People considering medication after an exposure should consult a healthcare professional, who can assess eligibility, timing, other medicines, and the current prescribing information.